| 產品描述： | Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively |
| 靶點： |
β2 adrenoceptor:9.6 (pEC50);β1 adrenoceptor:6.1 (pEC50);β3 adrenoceptor:5.9 (pEC50);HIVProtease;?AdrenergicReceptor |
| 體內研究： |
Salmeterol (0.16 mg/kg), Formoterol (0.32 mg/kg) and combined treatment have therapeutic effects in mice with chronic obstructive pulmonary disease (COPD) |
| 參考文獻： |
1. Panayiotis A Procopiou, et al. The discovery of long-acting saligenin β? adrenergic receptor agonists incorporating a urea group. Bioorg Med Chem. 2011 Oct 15;19(20):6026-32. 2. Malcolm Johnson. Effects of beta2-agonists on resident and infiltrating inflammatory cells. J Allergy Clin Immunol. 2002 Dec;110(6 Suppl):S282-90. 3. Zhiyuan Wang, et al. Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease. Exp Ther Med. 2018 Feb;15(2):1538-1545. |
| 溶解性： |
DMSO : ≥ 50 mg/mL (82.82 mM) |
| 保存條件： |
2-8℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
1.656 ml |
8.282 ml |
16.563 ml |
| 5 mM |
0.331 ml |
1.656 ml |
3.313 ml |
| 10 mM |
0.166 ml |
0.828 ml |
1.656 ml |
| 50 mM |
0.033 ml |
0.166 ml |
0.331 ml |
|
| 注意： |
部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經營許可證（不帶存儲）
營業執照(三證合一)
北京